Evidence map›Paper›PMID 41027741›Full record

ArticleRenal failure2025

Taohong Siwu Decoction relieves renal fibrosis: based on network pharmacology and experimental confirmation.

Xiao-Qian Zhang, Yi Gong, Yi-Han Wang, Hong-Wei Su, Rui-Zhi Tan, Jun-Ming Fan, Li Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiao-Qian ZhangDepartment of Nephrology, The Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.
Yi GongDepartment of Nephrology, The Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.
Yi-Han WangDepartment of Nephrology, The Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.
Hong-Wei SuDepartment of Urology, The Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.
Rui-Zhi TanResearch Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Jun-Ming FanDepartment of Nephrology, The Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.ORCID 0000-0003-2213-4782
Li WangResearch Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal fibrosis is a critical process in chronic kidney disease (CKD) that can progress to end-stage renal disease (ESRD). Taohong Siwu Decoction (THSWD) has shown potential for anti-fibrotic effects, but its underlying mechanisms remain unclear.

objectiveTo investigate the anti-fibrotic mechanisms of THSWD using network pharmacology and cellular validation.

methodsActive components and targets of THSWD were identified. Analyses of drug-component-target networks and protein interactions were conducted. Functional enrichment and molecular docking assays were performed. Western blotting was used to evaluate epithelial-mesenchymal transition (EMT) markers (E-cadherin, Twist, N-cadherin, Vimentin, α-SMA, Fibronectin) and proteins in the Phosphoinositide 3-Kinase (PI3K)/Protein Kinase B (AKT)/Glycogen Synthase Kinase-3β (GSK-3β) pathway in TGF-β-stimulated TCMK1 cells.

resultsTHSWD comprises 61 active components and 213 targets, 59 of which overlap with renal fibrosis targets. Enrichment analyses highlighted the IL-11 and PI3K/AKT pathways. Molecular docking identified β-sitosterol as a key component. In TGF-β-stimulated cells, β-sitosterol (5-20μmol·L

conclusionTHSWD, primarily through β-sitosterol, alleviates renal fibrosis by modulating the PI3K/AKT/GSK-3β signaling pathway and EMT process (

Indexed as

Drugs, Chinese HerbalKidneyRenal Insufficiency, ChronicCell LineEpithelial-Mesenchymal TransitionFibrosisGlycogen Synthase Kinase 3 betaHumansMolecular Docking SimulationNetwork PharmacologyProto-Oncogene Proteins c-aktSignal TransductionSitosterolsTransforming Growth Factor betaDrugs, Chinese HerbalGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktSitosterolsTransforming Growth Factor betanetwork pharmacologyPI3K/AKT/GSK-3β pathwayrenal fibrosisTaohong Siwu Decoctionβ-sitosterol

Identifiers

PMID41027741
PMCPMC12486456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.